Telix Pharmaceuticals Limited is a clinical-stage biotechnology company dedicated to the development and commercialisation of molecularly-targeted radiation (MTR) therapy. Our products seek to address major clinical unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.
Our mission is
to help patients
with cancer live longer
with better quality lives
$TLX is delighted to announce our commercial collaboration with Nihon Medi-Physics #NMP in #renalcancer for the Japanese market. NMP is a JV between @GEHealthcare and #Sumitomo chemical and a leading Japanese nuclear medicine company.